Kelun-Biotech's Sacituzumab Tirumotecan and Two Other Cancer Drugs Selected for ASCO 2026 Oral Presentations

Key Takeaways

• Kelun-Biotech will present clinical data for three cancer treatments at the prestigious ASCO 2026 Annual Meeting in Chicago
• The presentations include results for TROP2 ADC sacituzumab tirumotecan, RET inhibitor lunbotinib fumarate, and a novel antibody-drug conjugate
• Oral presentations at ASCO represent significant clinical achievements and could accelerate regulatory pathways for these oncology treatments

---

Kelun-Biotech Secures Three Oral Presentations at ASCO 2026

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) announced that three of its clinical studies have been selected for oral presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for May 29 to June 2 in Chicago.

Featured Drug Candidates

The presentations will showcase clinical data for sacituzumab tirumotecan (sac-TMT), a TROP2-targeted antibody-drug conjugate marketed as Jiatailai®. This represents a significant milestone for the company’s oncology pipeline, as ASCO oral presentations are highly competitive and reserved for the most impactful clinical findings.

Additionally, Kelun-Biotech will present results for lunbotinib fumarate (A400/EP0031), branded as Ningtailai®, which is positioned as a next-generation selective RET inhibitor. The third presentation will cover data from the company’s novel antibody-drug conjugate platform.

Market Implications

ASCO oral presentations often serve as catalysts for regulatory discussions and partnership opportunities. For Kelun-Biotech, these presentations could strengthen its position in the competitive oncology market, particularly in the rapidly expanding ADC sector where TROP2-targeted therapies have shown promising efficacy across multiple tumor types.

The selection of three studies for oral presentation demonstrates the breadth of Kelun-Biotech’s clinical pipeline and validates its research capabilities on an international stage. This recognition could enhance investor confidence and attract potential collaboration partners as the company advances these candidates through late-stage development.

Clinical Development Timeline

While specific trial details and patient populations were not disclosed in the announcement, the ASCO presentations will likely provide crucial efficacy and safety data that could inform future regulatory submissions and market access strategies for these investigational treatments.

---

Frequently Asked Questions

What does this ASCO selection mean for patients?

ASCO oral presentations typically showcase promising clinical results, suggesting these treatments may offer new therapeutic options for cancer patients, though regulatory approval is still required.

When will sacituzumab tirumotecan be available to patients?

The timeline depends on current trial phases and regulatory review processes. ASCO data presentations often precede regulatory submissions by 6-18 months.

How does sacituzumab tirumotecan compare to other TROP2 ADCs?

Direct comparisons will be clearer after the ASCO presentation, but sacituzumab tirumotecan represents Kelun-Biotech’s approach to targeting TROP2-expressing tumors with their proprietary ADC technology.

Related coverage

• Kelun-Biotech Secures New Drug Approval for SKB118: Investor and BD Guide
• Minghui and Qilu Pharmaceutical Unveil Promising MHB088C Data in mCRPC at ASCO 2026
• ASCO 2026: Asian Oncology Innovation Takes Center Stage, Driving Global Clinical Trial Advancements